33 results
8-K
EX-10.4
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
any lien (statutory or other), encumbrance, charge, mortgage, pledge, security interest, title defect, claim, community property interest, condition
8-K
92iwi91v
26 Oct 22
Regulation FD Disclosure
9:00am
8-K
EX-99.1
j5ua4v 1y3
16 Aug 22
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:20am
424B5
qpnq4jv zxhri
1 Dec 21
Prospectus supplement for primary offering
2:28pm
10-KT
p0b0fwfg nvtq
31 Mar 21
Annual report (with FYE transition)
4:33pm
424B5
acx95m82ugi df
18 Dec 20
Prospectus supplement for primary offering
1:26pm
424B5
mg7ygd
2 Oct 20
Prospectus supplement for primary offering
4:24pm
424B5
a6zbyhxr1 4lc
4 Aug 20
Prospectus supplement for primary offering
6:16am
424B5
fqn wnxivxs
10 Jul 20
Prospectus supplement for primary offering
2:35pm
424B3
1hs49t9q3h9hf
9 Apr 20
Prospectus supplement
9:30am